Test Your Knowledge of CLL Presented at ASH!
Do you remember the CLL research presented at ASH 2024? Test your knowledge now and see how you rank!
Feb 19, 2025
MEETING BRIEF
ASH 2024 – CLL/SLL
The latest news from ASH 2024 focused on chronic lymphocytic leukemia (CLL) including abstracts, features, and helpful conference information.
CLL/SLL: Treatment Updates, Improving QOL, and More
CLL/SLL: Treatment Updates, Improving QOL, and More
A curated roundup of what happened at ASH 2024, focused on CLL/SLL - treatment updates, improving QOL, and novel agents.
Treatment Sustains Clinical Benefit Over Two Years in R/R CLL, SLL
Treatment Sustains Clinical Benefit Over Two Years in R/R CLL, SLL
Liso-cel shows durable efficacy in R/R CLL/SLL, with extended OS of 43.2 months, high uMRD rates, and consistent safety after nearly two years of follow-up.
Assessing QOL and Treatment Impact in Asymptomatic Early-Stage CLL
Assessing QOL and Treatment Impact in Asymptomatic Early-Stage CLL
The CLL 12 study found ibrutinib improved global health/physical function without overall survival benefits in early-stage, asymptomatic CLL.
Treatment Combo Provides Consistently High PFS in CLL, SLL
Treatment Combo Provides Consistently High PFS in CLL, SLL
First-line, fixed-duration ibrutinib plus venetoclax provides durable progression-free survival and overall survival for patients with CLL or SLL.
Advertisement
PW QUIZ
Advertisement
Stay connected to the latest news with Physician’s Weekly
Insights from the leaders in medical research, trending topics in clinical medicine, and perspectives from your colleagues.
Subscribe to our free Newsletters to receive weekly emails, and even get a laugh or two from our medical cartoons.
